

Final Version March 23

Program „Driving Academic Translation of Cell and Gene Therapies (CGT)“, Berlin 30/31.3.23

Location: Maritim Pro Arte Hotel, Friedrichstrasse 151, 10117 Berlin

Day 1 (March 30th)

Morning:

- 9.30 Welcome
- Hans-Dieter Volk, Berlin: RESTORE Health by Cell and Gene Therapy – Aims of the meeting” (15 min)
 - Christopher Baum, Berlin: Strategy for a Berlin Hub on CGT (15 min)
- 10.00 Case Study Session 1: European Multicenter Networks and Use Cases
(Chairs: Annette Künkele, Berlin, DE and Reno Debets, Rotterdam, NL)
- Johan v. Eldere, Leuven, BE: “European Center for Cell and Gene Cancer Therapy (EUCCAT)” (20+5 min)
 - Carmen Sanges, Würzburg, DE: “ How to boost the development and increase accessibility of engineered T cell Therapies in Europe: a Translational Ecosystem concept” (20+5 min)
 - Petra Reinke, Berlin, DE: “ReSHAPE undesired immunity by next-generation regulatory T cells” (20+5 min)
 - Silvia Martin Lluesma, Barcelona, ES: “Pragma TIL project or implementing TIL at PoC in a multicenter study – mapping regulatory hurdles” (20+5 min)
- 12.00 Discussion Round 1: Measures of Translation
(Chairs: Peter Van der Made, Berlin, DE and Hans-Dieter Volk, Berlin, DE)
- Intro: H.-Dieter Volk, Berlin, DE: “ToMAP model - Entry, Assess, Check, Reward Translation” (15 min)
 - Panel discussion

12.30 Lunch

Afternoon:

- 14.00 Case Study Session 2
(Chairs: Carmen Sanges, Würzburg, DE and Johann v. Eldere, Leuven, BE)
- Reno Debets, Rotterdam, NL: “MAGE-C2 TCR T cell trial: current status and future outlook” (20+5)
 - Renata Stripecke, Cologne, DE: “CAR-T cells against EBV positive malignancies” (20+5 min)
- 15.00 Discussion Round 2 “Regulatory Hurdles of Clinical Development and Therapy Monitoring”
(Chairs: Leila Amini, Berlin, DE and Sean Russel, Milan, IT)
- Sean Russel, Milan, IT: “Regulatory hurdles of translating CGT from bench to commercialization” (10 min)
 - Leila Amini, Berlin, DE: “Hurdles of process development from Research to GMP level” (10 min)
 - H.-Dieter Volk, Berlin, DE : “Therapy Monitoring” (10 min)
 - Panel discussion
- 16.00 Coffee Break
- 16.30 Case Study Session 3
(Chairs: Antonia MS Müller, Vienna, AT and Petra Reinke, Berlin, DE))
- Michael Schmück-Henneresse, Berlin, DE: “Harnessing chemokine systems for therapeutic modulation of the tumor microenvironment“ (20+5 min)
 - Theresa Käuferle, Munich, DU: “TRACE – virus-specific T cells in a multinational phase III study” (20+5 min)
 - Sven Geissler, Berlin, DE: “The HIPGEN phase III study - placental derived stromal cells for muscle regeneration in hip fracture patients” (20+5min)

Evening

- 19.00 Networking Dinner.
Restaurant Heritage, Charlottenstraße 52 (10 minute walk from hotel, for registered participants only)

Day 2 (March 31st)

Morning:

09.00 Platform Technologies Session 1

(Chairs: Simone Spuler, Berlin, DE and Renata Stripecke, Cologne, DE)

- Oumeya Adjali, Nantes, FR "Advanced murine models for preclinical testing of CGT" (20+5 min)
- Dimitrios L. Wagner, Berlin, DE: "Multiplex gene/base editing – opportunities and hurdles" (20+5 min)

10.00 Discussion Round 3: Gene/Base/Epigenetic Editing

(Chairs: Ciaran Lee, Cork, IE and Dimitrios L. Wagner, Berlin, DE)

- Intro: Ciaran Lee, Cork, IE: "Off-Target Identification" (15 min)
- Panel discussion

10.45 Coffee break

11.15 Case Study Session 4

(Chairs: Renata Stripecke, Cologne, DE and Michael Schmück-Henneresse, Berlin, DE)

- Shaheer Bardissi, Cairo, EG: "Affordability and accessibility of CGT for developing countries" (20+5)
- Simone Spuler, Berlin, DE: "Gene editing for genetic muscle diseases" (20+5 min)

12.15 Concluding Remarks

- Hans-Dieter Volk

12.30 End of meeting

Organization Team

Kristina Helen Dewsbery, Anne Schwerk

Scientific Program

Hans-Dieter Volk, Peter Van der Made, Petra Reinke, Leila Amini, Michael Schmück-Henneresse, Dimitrios L. Wagner